Nuvalent (NASDAQ:NUVL) Reaches New 52-Week High – Here’s Why

Shares of Nuvalent, Inc. (NASDAQ:NUVL) hit a new 52-week high on Tuesday . The stock traded as high as $122.88 and last traded at $122.8550, with a volume of 13794712 shares trading hands. The stock had previously closed at $88.49.

Key Headlines Impacting Nuvalent

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: Nuvalent agreed to be acquired by GSK for roughly $10.6 billion in cash, valuing the cancer drug developer at a substantial premium and sending the stock sharply higher. Reuters: UK’s GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
• Positive Sentiment: The deal gives GSK ownership of three lung cancer drug candidates, including two that are already under FDA review, highlighting the value of Nuvalent’s pipeline and supporting the takeover price. WSJ: GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
• Neutral Sentiment: Market commentary also notes the deal is part of GSK’s broader effort to strengthen its oncology franchise and offset future patent pressure in other businesses, which explains the strategic rationale behind the acquisition. Proactive Investors: GSK agrees $10.6bn Nuvalent takeover to bolster oncology pipeline

Wall Street Analysts Forecast Growth

Several research firms have recently commented on NUVL. Lifesci Capital restated a “market perform” rating and set a $124.00 price target on shares of Nuvalent in a research note on Tuesday. Wedbush reiterated a “neutral” rating and issued a $124.00 price objective (down from $125.00) on shares of Nuvalent in a research report on Tuesday. Sanford C. Bernstein assumed coverage on shares of Nuvalent in a research note on Thursday, May 21st. They issued an “outperform” rating and a $189.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $155.00 price objective on shares of Nuvalent in a research report on Tuesday, April 21st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Nuvalent in a research note on Tuesday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Nuvalent currently has an average rating of “Moderate Buy” and a consensus target price of $140.22.

Nuvalent Trading Up 38.9%

The business has a 50 day moving average price of $102.38 and a 200-day moving average price of $102.97. The firm has a market capitalization of $9.71 billion, a PE ratio of -20.28 and a beta of 1.15.

Nuvalent (NASDAQ:NUVL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same quarter in the previous year, the firm posted ($1.18) earnings per share. On average, equities research analysts forecast that Nuvalent, Inc. will post -5.74 earnings per share for the current year.

Insider Activity at Nuvalent

In other Nuvalent news, CFO Alexandra Balcom sold 11,430 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $98.69, for a total transaction of $1,128,026.70. Following the sale, the chief financial officer directly owned 85,533 shares in the company, valued at approximately $8,441,251.77. The trade was a 11.79% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James Richard Porter sold 30,000 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $101.69, for a total transaction of $3,050,700.00. Following the completion of the transaction, the chief executive officer owned 324,879 shares of the company’s stock, valued at $33,036,945.51. This represents a 8.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 96,953 shares of company stock valued at $9,956,364 over the last 90 days. Company insiders own 5.02% of the company’s stock.

Institutional Investors Weigh In On Nuvalent

A number of hedge funds and other institutional investors have recently modified their holdings of NUVL. Bank of America Corp DE grew its holdings in shares of Nuvalent by 20.0% in the 1st quarter. Bank of America Corp DE now owns 216,516 shares of the company’s stock worth $22,182,000 after acquiring an additional 36,147 shares during the period. Tri Locum Partners LP increased its stake in Nuvalent by 0.4% in the 1st quarter. Tri Locum Partners LP now owns 308,506 shares of the company’s stock valued at $31,606,000 after purchasing an additional 1,135 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in Nuvalent by 141.3% during the first quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock worth $34,000 after purchasing an additional 195 shares during the last quarter. California State Teachers Retirement System boosted its position in Nuvalent by 29.7% during the first quarter. California State Teachers Retirement System now owns 49,670 shares of the company’s stock worth $5,089,000 after purchasing an additional 11,386 shares in the last quarter. Finally, Royal Bank of Canada boosted its position in Nuvalent by 1,537.9% during the first quarter. Royal Bank of Canada now owns 23,569 shares of the company’s stock worth $2,414,000 after purchasing an additional 22,130 shares in the last quarter. 97.26% of the stock is currently owned by institutional investors and hedge funds.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.